CA 125, a New Prognostic Marker for Aggressive NHL.
CA 125 was evaluated in the sera of patients with aggressive NHL, together with LDH and β2m, in a trial to assess its value in the diagnosis and follow-up, and to compare it to some prognostic factors. The study included 78 newly diagnosed patients with diffuse large B cell non-Hodgkin's lymphoma (DLBCL), with age range 18-60 years, and a WHO performance status of 0, I or II, in addition to twenty apparently healthy controls. All patients received CHOP regimen for 6 cycles. The levels of CA 125 and LDH were significantly higher in DLBCL compared to the control group (p-value = 0.031 and = 0.009, respectively). Cutoff levels used were 20U/ml, 310 U/L, and 2mg/l for CA125, LDH and β2m, respectively. CA125 serum level was high in 55%, LDH level in 72%, and β2m level in 62% of patients. As regards the stage, CA 125 was elevated in 17%, 52%, 80%, and 100% of patients in stage I, II, III, and IV, respectively. CA 125 was elevated in 81.3% of patients with bulky disease, in 83.3% presenting with involvement of more than 1 extranodal site, and in 90% presenting with effusion. The highest levels of CA125, LDH, and β2m were observed in stage IV, and lowest in stage I (p-value<0.001, 0.005, and 0.154, respectively). There was also a significant positive correlation between CA 125 and LDH (p-value <0.001). CA 125 showed specificity of 80% with 95% CI (56- 94), and LDH showed sensitivity of 72% with 95% CI (60-81). Complete response to treatment was achieved in 71.8% of our patients. Survival at 24 months was 78.2%. There was a statistically significant increase in survival in patients with CA125<20U/ml, patients with LDH<310U/L, and patients with β2m<2mg/l (p-value = 0.006, 0.025, and 0.042, respectively). A shorter disease-free survival was associated with increased CA 125 (p<0.001). CA125 was found to correlate with stage, tumor bulk, involvement of more than 1 extranodal site, and presence of effusion. Elevated levels of CA 125 and LDH were found to predict decreased survival. Initial measurement of CA125 may, therefore, provide valuable prognostic information. CA125 - LDH - β2m, NHL - DLBCL.